Skip to content
Biodatica
Start free

Affidea Nu-med Center of Oncological DIagnostics and Therapy

Zamość, Lublin Voivodeship

OncologyPhase III
Compare Sign in to watch

What changed

Study registered, no phase assigned: PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer

1w agoTrial registeredJul 9, 2026Source filing (opens the source filing in a new tab)

Momentum

81no change

Momentum 81 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

561 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jun 26, 2026

    Oligoprogressive Prostate Cancer, Metastatic Prostate Cancer · RECRUITING · sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy · PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer

    ClinicalTrials.gov · NCT07691697 (opens the source filing in a new tab)

  2. Trial

    PHASE2/PHASE3 registered

    Mar 19, 2026

    Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy, Stereotactic Body Radiation Therapy (SBRT), Dose Escalation: Solid Tumors, Localized Prostate Cancer · RECRUITING · sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy · PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer

    ClinicalTrials.gov · NCT07426055 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources